LifeSci Capital initiated coverage of Monte Rosa Therapeutics (GLUE) with an Outperform rating and $19 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter